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The present study was carried out to test the colonic mucosal response of rats to oral supplementation with Lactobacillus fer-
mentum BGHI14 and to correlate the tissue reaction to trinitrobenzenesulfonate (TNBS)-induced colitis with mucosal barrier
alterations caused by bacterial ingestion. An immune cell-mediated reaction of healthy colonic tissue was noticed after bacterial
feeding. After prolonged bacterial treatment, the observed reaction had retreated to normality, but the mRNA levels of proin-
flammatory cytokines interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-) remained elevated. These data point to
the chronic low-grade inflammation that could be caused by long-term probiotic consumption. Although no detrimental effects
of bacterial pretreatment were noticed in colitic rats, at least in the acute state of disease, the results obtained in our study point
to the necessity of reassessment of existing data on the safety of probiotic preparations. Additionally, probiotic effects in experi-
mental colitis models might depend on time coordination of disease induction with treatment duration.
Gut microorganisms are considered highly beneficial to thehost, and disturbance of gut microflora due to inadequate
nutrition or antibiotic treatment has been associated with loss of
homeostasis and development of gastrointestinal (GI) pathologies
(1, 2). Dietary management of aberrant gut microbiota can be
achieved by administration of noncommensal beneficial mi-
crobes, commonly named probiotics. Nutritional supplements,
usually lactobacilli and bifidobacteria of gastrointestinal origin,
have been developed relying on the knowledge of the gut micro-
biota composition of the healthy host (3–5). The coexistence of a
large number of symbionts in close proximity to immunologically
“armed” mucosal tissue is explained by luminal sequestration of
commensals by the host’s barrier mechanisms. Beneficial bacteria
interact with pattern recognition receptors (PRR) on epithelial
cells and induce innate mucosal responses (6) through direct and
indirect stimulation of enterocytes and lamina propria phago-
cytes. Subsequently, cells initiate mucosal cross talk that is essen-
tial for maturation and maintenance of barrier integrity. These
interactions are regulated through the release of cytokines, includ-
ing interleukin-6 (IL-6), transforming growth factor  (TGF-),
and tumor necrosis factor alpha (TNF-), by epithelial cells and
underlying phagocytes. This is how commensals keep the mucosa
in an alert state prepared for the eventual pathogen encounter.
Although the initial reaction of harmless bacteria would stimulate
innate cytokine production by epithelial and phagocytic cells, no
disruption of the epithelial barrier occurs (6). Probiotic therapy
has often been employed for treatment of intestinal inflamma-
tions. Studies using animal models of intestinal inflammation
demonstrated that impaired innate immune responses lead to ex-
acerbation of tissue pathology (4, 7). Themost commonly studied
animal model for bowel inflammation is the trinitrobenzenesul-
fonate (TNBS)-induced colitis model presented by transmural in-
flammation of colonic wall after intrarectal TNBS instillation (8).
Lactobacillus treatment has proved to be effective in TNBS-in-
duced inflammation (9). Acting as antigenic stimuli, administered
lactobacilli can promote a time-varying response in mucosal tis-
sue (10), which should be considered when testing the protective
effects of the potential probiotics in established colitismodels. The
aim of our study was to test the effect of Lactobacillus fermentum
BGHI14 on the intensity of the TNBS-invoked mucosal lesion
after 14 days of bacterial treatment, which is the most commonly
used time point for studying the preventive effects of probiotics in
TNBS colitis. To gain comprehensive information on the state of
mucosa in the moment of lesion induction, we monitored time
changes in healthy mucosa continually exposed to bacteria. Ex-
pression of proinflammatory cytokines TNF-, IL-1, and IL-
17F, as well as that of barrier protective elements, including cyto-
protective and intercellular junction proteins, was analyzed.
MATERIALS AND METHODS
Preparation of bacteria. Lactobacillus fermentum strain BGHI14, isolated
from newborn feces of a breast-fed infant 2 weeks after the birth, was used
in the study. Bacteria were cultivated in De Man-Rogosa-Sharpe (MRS)
medium (Merck GmbH, Darmstadt, Germany) at 37°C anaerobically in
an anaerobic jar (Merck) using Anaerocult A (Merck). For the animal
treatment, 10 ml of overnight culture (containing in total 2 1010 to 3
1010 bacteria) was pelleted, washed in saline, and finally resuspended in 1
ml of 11% sterile skimmedmilk (ADMlekara Subotica, Subotica, Serbia),
as described by Geier et al. (11).
Animals. Female Wistar rats of the same litter, 5 to 6 weeks old, were
purchased from the Farm of theMilitaryMedical Academy, Belgrade, and
for research purposes were housed in the animal facility at the Faculty of
Pharmacy, University of Belgrade. After 3 days of adaptation to the exper-
imentation environment, at the onset of the experiment, the animals
weighed 140  10 g. Rats were housed in cages, four per room, with a
controlled 12-h-light/12-h-dark cycle and had unlimited access to stan-
dard rat food and tap water. Cages were maintained clean, and bedding
was changed daily. All experimental procedures and protocols conformed
to institutional guidelines for the care and use of animals in research no.
2/09 (Ethics Committee of the Faculty of Pharmacy, University of Bel-
grade). Animal manipulations were approved by the Ethical Committee
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for Experimentation on Laboratory Animals of the Faculty of Pharmacy,
University of Belgrade.
Study design. Animals (n 48) were allocated to six groups (n 8)
(Fig. 1) and gavaged daily using a stainless steel 18-gauge feeding tube
(Instech Solomon, PlymouthMeeting, PA). For the first 15 days, rats from
three bacterium-treated groups received 1 ml of prepared bacterial sus-
pension in skimmedmilk and rats from three control groups received 1ml
of sterile skimmedmilk every day. The rat’s body weight was recorded on
a daily basis throughout the experiment. On day 15, after 36 h of fasting,
animals from one bacterium-treated group and one control group were
rendered colitic using a 34% solution (vol/vol) of 1 M TNBS (Fluka,
Buchs, Switzerland) resuspended in 50% ethanol. Rats were administered
100  10 l of prepared TNBS solution per 100 g of body weight (12)
using a rubber catheter (Ch6; Romed Holland, Wilnis, Netherlands) in-
serted 6 cm proximally from the anus (13). The other four control groups
named as healthy bacterium-treated and healthy control groups, depend-
ing on previous treatment, received the same dose of phosphate-buffered
saline (PBS) (shamcontrol). The next day (day 16), the ratswere treated in
the same way. On day 17, 48 h after TNBS or PBS administration, over-
night-fasted animals from two colitic groups and from two healthy 16-day
groups were sacrificed by increasing the CO2 concentration. The colon
from each rat was removed aseptically and opened longitudinally, and the
luminal content was washed out with saline. Tissue segments 3 cm prox-
imally from the anus, including all colonic wall layers, were sampled. For
histological assessment, tissue was fixed in 10% formalin (14). FormRNA
isolation, tissuewas immediately frozen at70°C. Luminal contents from
distal intestine of 4 healthy control and 4 healthy bacterium-treated rats
were removed and frozen at 70°C for detection of BGHI14 survival in
the GI tract. On day 17, for the rats from remaining two groups (the
healthy 28-day bacterium-treated group and the healthy 28-day control
group), the same treatment continued for next 12 days. On day 29, after
overnight fasting, rats were sacrificed, and sampling of colonic tissue was
done as described above.
DGGE analysis. Extraction of bacterial DNA from frozen samples was
done using the QIAamp DNA stool minikit (Qiagen, Hilden, Germany).
PCR with isolated genomic DNA as a template was set up according to
Heilig et al. (15), except for the cycle number, which was decreased to
avoid amplification of nonspecific fragments (16). Lactobacillus-specific
primer set Lab-0159f and Uni-0515-GCr (Metabion International, Mar-
tinsried, Germany) was used. The primer sequences are given in Table 1.
Amplification was performed using KAPA Taq DNA polymerase (KAPA
Biosystems, Cape Town, South Africa). The reaction was performed in
thermal cycler Gene AmpR PCR system 2700 (Applied Biosystems, Foster
City, CA). Denaturing gradient gel had been prepared as described by
Heilig et al. (15) using glass plates for the denaturing gradient gel electro-
phoresis (DGGE) apparatus DGGE-2001 (C.B.S. Scientific, San Diego,
CA). USAGel manipulation after electrophoresis was performed accord-
ing to Radojkovic et al. (17).
DGGE fragment sequencing. Fragments of interest were excised from
the gel and macerated, and the suspension was incubated for 10 min at
98°C (18). After incubation, the suspension was centrifuged to pellet gel
particles. The supernatant (30 l) was used in PCR with Lab-0159f and
Uni-0515r primers. The obtained PCR products were purified using the
QIAquick PCR purification kit (Qiagen) and ligated into the pGEM-T
Easy vector system (Promega, Fitchburg, WI) according to the manufac-
turer’s instructions. Ligated constructs were transformed in Ca2-in-
duced competent DH5 cells (19), and insert-containing transformants
were selected as white colonies on Luria agar (LA) plates containing 100
gml1 ampicillin and 20gml1 X-Gal (5-bromo-4-chloro-3-indolyl-
-D-galactoside) as recommended by Promega. For each excised DNA
band, one white colony was picked and plasmids were isolated using the
QIAprep spin miniprep kit (Qiagen). The sequencing of the isolated in-
sert-containing pGEM-T Easy vectors was done with M13F/R primers
at Macrogen Europe Service, Amsterdam, Netherlands (http://dna
.macrogen.com/eng/support/seq/seq_uniprimer.jsp).
FIG 1 Study design.
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Histological analysis. Formalin-fixed colonic tissue was processed for
histopathological observation with the protocol adapted from various
sources (14, 20, 21). Paraffin blocks were cut on a rotary microtome
(RM2125RT, Leica Microsystems, Wetzlar, Germany). Staining of tissue
was performed using manually prepared Mayer hematoxylin and eosin
(H&E) solutions. Slides were inspected under a Nikon microscope
(Nikon Instruments, Inc., Tokyo, Japan). Colon damage was evaluated by
pathologist who was blinded to the experimental groups. Scoring was
done semiquantitatively on a scale from 0 to 9modified from Farooq et al.
(22), assuming inflammation intensity (score of 0 to 5), crypt architec-
tural changes (score of 0 to 3), and edema presence (score of 0 or 1).
Histological sections were photographed usingNIS-Elementsmicroscope
imaging software 2.3 (Nikon Instruments Inc.).
mRNA isolation. Extraction of mRNA for quantitative PCR (qPCR)
analysis was done according to Chomczynski et al. (23) with slight mod-
ifications. Tissue was pulverized in liquid nitrogen and resuspended in
denaturing solution (4 M guanidine thiocyanate, 25 mM sodium citrate,
0.1 M -mercaptoethanol, 0.5% [wt/vol] N-lauroylsarcosinate sodium
salt). Two acid phenol (pH 4) extractions were performed. After isopro-
panol precipitation, the pellet was again resuspended in denaturing solu-
tion and the phenol extraction step was repeated. All isolation steps were
performed restricted to the precautions for RNA handling. Isolated RNA
was stored at70°C until further manipulations.
Real-time PCR (qPCR).Reverse transcriptionwas performed accord-
ing to the protocol provided by the reverse transcriptase manufacturer
(Thermo Scientific). Random hexamers (Applied Biosystems) and Ribo-
Lock RNase inhibitor (Thermo Scientific) were utilized in the reaction.
Controls without reverse transcriptase were included for the genomic
DNA contamination check. All reaction steps were performed in the ther-
mal cycler Gene AmpR PCR system 2700 (Applied Biosystems).
Prepared cDNAwas amplified in qPCRs using the 7500 real-time PCR
system (Applied Biosystems) with the primer sets listed in Table 1. Prim-
ers (Invitrogen, Paisley, United Kingdom) were designed utilizing
Primer3 software, available online (http://frodo.wi.mit.edu). The reac-
tion and cycling were done as recommended by the manufacturer of the
KAPA SYBR Fast universal master mix (KAPA Biosystems). The condi-
tions of the two-step qPCRwere set as follows: activation for 3min at 95°C
followed by 40 cycles of 15 s at 95°C and 60 s at 60°C. In relative quanti-
fication analysis, a 1/10 dilution of cDNA template was used with sample
from the control 16-day treatment group set as a calibrator. Controls
without reverse transcriptase were amplified to ensure that DNA contam-
ination in the isolated mRNA is acceptable (24).
Data presentation and statistical analysis. Results are presented as
mean values with standard errors graphically using column bar charts,
and differences are reported as statistically significant if P (two tailed) is
	0.05. Data normality was evaluated by the Shapiro-Wilk test, and nor-
mally distributed data were analyzed using a two-sample Student’s t test
assuming unequal variances. Nonnormally distributed data were log10
transformed, and if the transformed data were normal, the t test was
applied as described above. If the normality could not be achieved by
transformation, a nonparametric Mann-Whitney U test was applied
on nontransformed results. Statistical analyses were performed using
SPSS 12.0 for Windows. Graphs were drawn in Microsoft Office Excel
2007.
RESULTS
Body weight assessment. During the treatment, the body weight
of rats was assessed on a daily basis. Rats belonging to both 16-day
and 28-day healthy control groups showed similar patterns inweight
changes during first 16 days of treatment and differed from the pat-
terns obtained for both 16-day and 28-day healthy bacterium-
treated rats (Fig. 2A and B). On day 12 from the beginning of the
treatment, in the case of healthy 16-day bacterium-treated groups,
bacterial treatment resulted in significant decrease (P	 0.05) in the
rats’ weights compared to those of the controls (Fig. 2A). For rats
belonging to thehealthy28-day treatment groups,weightdeclinedue
to bacterial treatment reached statistical significance (P 	 0.05) on
day 12 from the onset of the study (Fig. 2B). No weight differences
were detected during the rest of the treatment for all four healthy
groups. Rats from the bacterium-treated colitic group didn’t present
a statistically significantweightdifferenceat any timepoint compared
tocolitic control rats (Fig. 2C).According todirectobservationof rats
in the course of the experiment, bacterial intake led to slight drops in
body masses that became most conspicuous
2 weeks after the be-
ginning of the treatment.
Detection of the BGHI14 bacterial strain. Ileal content taken
from rats after sacrifice was analyzed as an indicator of microflora
composition. The DGGE profile of 16S rRNA gene amplicons
obtained from pure culture of BGHI14 strain revealed the exis-
tence of several copies of the 16S rRNA gene, with one copy stain-
ing most intensively on the gel. DGGE analysis of 16S rRNA
products obtained from ileal contents of 2 of 4 analyzed bacteri-
um-treated rats revealed the band corresponding to the dominant
band obtained with DNA isolated from strain BGHI14 (Fig. 3).
Suspected bands as well as the dominant pure culture band were
TABLE 1 Primers used in this study
Primer name Primer sequence (5=¡3=) Source or reference
Lab-0159f GGA AAC AG (A/G) TGC TAA TAC CG 15
Uni-0515r ATC GTA TTA CCG CGG CTG CTG GCA 15
Uni-0515-GCr ATC GTA TTA CCG CGG CTG CTG GCA CGC CGG GGG CGC GCC
CCG GGC GGG GCG GGG GCA CGG GGG G
15
-Actin forward AGC CAT GTA CGT AGC CAT CC 50
-Actin reverse CTC TCA GCT GTG GTGGTG AA 50
Tjp1 forward GCA GTG TGA ACA TGG ATT GAA This work
Tjp1 reverse AGC CAA TGC CTG ACA GTT CT This work
Hsp70 forward CGC TCC AGG TGT GAT CTA GG This work
Hsp70 reverse TAC TGG GAA TGC AAA GCA CA This work
IL-17F forward GGA AAA GCC TCC TTT GAT CC This work
IL-17F reverse ACG GAG CTT CAA GGA TGT TG This work
IL-1 forward GGA AGG CAG TGT CAC TCA TTG TG 51
IL-1 reverse GGT CCT CAT CCT GGA AGC TCC 51
TNF- forward AAA TGG GCT CCC TCT CAT CAG TTC 52
TNF- reverse TCT GCT TGG TGG TTT GCT ACG AC 52
L. fermentum-Colon Interaction
September 2013 Volume 79 Number 18 aem.asm.org 5737
FIG 2 Daily bodymass changes during the course of the study of bacterium-treated and control rats belonging to (A) healthy 16-day treated groups, (B) healthy
28-day treated groups, and (C) colitic groups. Probability (P) values obtained for group differences at the indicated time points are reported above the charts.
Lukic et al.
5738 aem.asm.org Applied and Environmental Microbiology
sequenced, and the sequences were queried against the NCBI ge-
nome collection. The results confirmed that all eluted bands be-
longed to Lactobacillus fermentum. No band corresponding to
dominant pure BGHI14 culture bandwas detected in control rats.
Along with the demonstration of the ability of BGHI14 to survive
in GI tract of the rats, results obtained by DGGE analysis showed
no significant shift in the ileal microbial community of the bacte-
rium-treated rats.
Histological evaluation. H&E staining was employed for
semiquantitative estimation of tissue reaction to bacteria and dis-
ease induction. Histological grading of colon tissue, assuming in-
flammation intensity, crypt distortion, and edema formation (Fig.
4), indicated a significantly higher (P 	 0.05) damage score in
both colitic bacterium-treated rats and colitic control rats com-
pared to healthy 16-day control rats but not in comparison to
healthy 16-day bacterium-treated rats. No differences in total
pathohistological scores were observed between the two colitic
groups. A significant increase (P	 0.05) in histological score was
observed in healthy rats receiving bacteria for 16 days compared to
healthy control rats. No edema formation or crypt architectural
changes were detected in healthy 16-day bacterium-treated rats
(Fig. 5). Although no statistical difference could be reached for
healthy 28-day rats relative to 16-day bacterium-treated rats, no
difference in pathohistological scores was observed between the
healthy 28-day bacterium-treated and control groups. Histologi-
cal grading pointed to an immune reaction caused by bacteria
after the administration in healthy rats but with no deleterious
effects of bacterial pretreatment in diseased rats.
Mucosal gene expression. Expression of inflammatory cyto-
kines as well as tissue cytoprotective and barrier maintenance fac-
tors was analyzed at themRNA level. Real-time PCR (qPCR) anal-
ysis of IL-1 transcript levels (Fig. 6A) indicated that TNBS
administration induced significantly higher IL-1 expression
than PBS administration (P 	 0.05). There was no difference in
levels of IL-1 mRNA induction between bacterium-treated and
control colitic rats. Nevertheless, healthy rats treated with bacteria
showed different tendencies in IL-1 transcription, depending on
the period of bacterial treatment. Sixteen days of bacterial treat-
FIG 3 Detection of BGHI14 in GI tract of treated rats. DGGE profiles of lactobacillus-specific 16S rRNA gene amplicons obtained in PCRs with Lab-0159f/
Uni-0515r set of primers. Arrows indicate eluted and sequenced bands. Lane 1, BGHI14 pure culture; lanes 2 to 5, ileal contents of four bacterium-treated rats;
lanes 6 to 9, ileal contents of four control rats; lane 10, PCR-negative control.
FIG 4 Pathohistological evaluation of the effect of bacterial treatment on colonic tissue morphology after induction of colitis in a defined time point (16 days)
and after two different periods (16 and 28 days) of treatment.
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ment did not have any influence on IL-1 expression in healthy
rats. Nevertheless, a 4-week bacterial treatment of healthy rats
resulted in a significant increase in IL-1mRNA synthesis relative
to that of the control (P	 0.05).
Colitis induction upregulated TNF-mRNA synthesis in dis-
eased rats relative to the healthy control group (P 	 0.05) (Fig.
6B). Bacterial feeding had no influence onTNF- transcription 48
h after colitis induction. Nevertheless, healthy 16-day as well as
28-day bacterium-treated rats presented significantly higher
TNF-mRNA expression than their control groups (P	 0.05).
TNBS administration significantly decreased IL-17F mRNA ex-
pressioncompared to that inhealthycontrol rats (P	0.05) (Fig. 6C).
No difference was detected in IL-17F mRNA levels between colitic
bacterium-treated and colitic control rats. Similarly, BGHI14 did not
influence IL-17F mRNA transcription in healthy rats. Bacterial pre-
treatment resulted in significantly higher heat shock protein 70
(Hsp70) mRNA transcription 48 h after colitis induction compared
to that in the colitic control group as well as the healthy 16-day bac-
terium-treated group (P 	 0.5) (Fig. 6D). No such difference was
detected relative to the healthy 16-day control group. Also, healthy
FIG 5 Histopathology of rat colonic tissue. (a) Cross-section of colonic tissue of bacteria-treated colitic rats exhibiting large submucosal infiltrates of polymor-
phonuclear cells. (b) Colitic control rats presenting a high damage score with crypt distortion andmassive neutrophil infiltration. (c) Healthy 16-day bacterium-
treated rats presenting diffuse submucosal accumulation of mononuclear cells, eosinophils, and occasional neutrophils. (d) Morphology in healthy 16-day rats.
(e) Occasional presence of mucosal and submucosal lymphocyte aggregates was noticed in healthy 28-day bacterium-treated rats. (f) Twenty-eight-day control
rats. Magnifications: a,600; b,200; c,100; d,200; e,200; f,100.
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28-day bacterium-treated rats as well as 28-day healthy control rats
presented significantly higherHsp70 transcript levels than the 16-day
corresponding groups (P	 0.05), but no effect of bacterial treatment
in healthy rats was observed.
Colitis induction had no influence on the Tjp1 (tight junction
protein 1)mRNA transcription (Fig. 6E). Also, BGHI14 treatment of
healthyandcolitic ratsdidnot induceTjp1mRNAtranscription.Rats
from the 28-day control group exhibited significantly higher Tjp1
mRNA expression than those from the 16-day control group (P 	
0.05).
RNAmessenger levelspoint to the inductionofkeyproinflamma-
tory cytokines inhealthy rats exposed toBGHI14, althoughnot to the
level detected in diseased rats. Additionally, induction of cytoprotec-
tive Hsp70 was noticed in colitic bacterium-treated rats.
DISCUSSION
Enrichment of gut microbiota with nonpathogenic bacteria
strengthens the host’s GI barrier actively shaping mucosal func-
tions (25). Most commonly tested potential probiotics are lacto-
bacillus strains that possess the plethora of highly desirable prop-
erties related to host health. Lactobacillus fermentum has long been
studied for its probiotic properties because of its human origin,
adherence capacity in GI tract, as well as protection in animal
models of bowel inflammation (26, 27). Experimental data also
support its role in mucosal barrier fortification (28). Also, clinical
trials including L. fermentum have been undertaken with promis-
ing results (27).
Due to vigorous conditions along the proximal intestine, the
first site of physiologically relevant (29) bacterial colonization is
the ileum (30), with lactobacilli being among most abundant res-
idents of this part of the gut (31). It is assumed that bacterial DNA
detection byDGGEanalysis of ileal luminal content is an indicator
of GI passage survival because the DNA of dead bacteria would
have been degraded by nucleases released in duodenal lumen (32).
Results obtained in our study indicated that L. fermentumBGHI14
FIG 6 Effect of BHGI14 on expression of (A) IL-1, (B) TNF-, (C) IL-17F, (D) Hsp70, and (E) Tjp1 mRNA in rats’ colonic tissue.
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successfully survives passage through the proximal part of the di-
gestive tract. Moreover, bacterium-treated rats displayed amicro-
flora profile that was similar to that of control rats. Probiotics
should not lead to perturbation of gut microflora of the healthy
host, as this could be an indicator of the invasive potential of
ingested microbes (33).
The immune reaction detected at a histological level in rats
exposed to L. fermentum BGHI14 for 16 days is an indicator of the
inflammatory response of the mucosal barrier to ingested bacte-
ria. Similarly, inflammatory cell infiltration has been observed in
lactobacillus-free mice inoculated with the closely related species
Lactobacillus reuteri (34). The large dose of lactobacillus given to
rats (
1010 bacteria/animal/day) might present an alarming sig-
nal to mucosal defense system, which in turn elicits effective in-
nate mechanisms to fight the unknown bacteria. This could be
taken as an indicator of the potential risk associatedwith probiotic
consumption in immunodeficient patients (33). According to the
rats’ weight changes, the peak of immune response to ingested
bacteria might have occurred several days earlier. Although the
treatmentwith bacteriawas continued for next 12 days, symptoms
of chronic inflammation were not observed, as evident from his-
tological data. Moreover, body weights of 28-day bacterium-
treated rats reached values similar to those of control rats.
Although the reaction of the healthy rat’s mucosa to lactoba-
cilli had retreated in spite of continued bacterial treatment, it can
be considered that, potentially, BGHI14 reached into deeper lay-
ers of mucosal tissue. The reaction of the healthy host to lactoba-
cillus treatment could be individual, and particular precautions
should be taken in the case of the immunocompromised host.
Stimulation of proinflammatory cytokines has been observed
after oral administration of lactobacilli, with cytokine production
ascribed to innate immune cells, includingmacrophages and den-
dritic cells (35). Treatment of healthy animals with BGHI14 in-
creased IL-1 and TNF- expression in healthy bacterium-
treated animals after 28 and 14 days, respectively. Both
proinflammatory cytokine levels remained increased, although
the initial innate immune cell-mediated reaction had subsided,
judging by the tissue sections. Both beneficial and detrimental
roles for TNF- have been described using animal models of in-
flammation, depending on the dose applied (36). A low TNF-
dose suppressed the infection, while a high TNF- dose, although
lessening the infection, was followed by serious inflammatory re-
action. However, chronic low-dose TNF- stimulation could lead
to cancerous cell growth (37). Contrary to TNF-, the primary
regulation of which resides at the transcriptional level, increased
IL-1mRNA levels indicate accumulation of inactive IL-1 pre-
cursor, which presents a danger in the case of inflammasome as-
sembly leading potentially to extensive inflammation (38). This
issue should be considered in cases of long-term lactobacillus sup-
plementation.
Synthesis of IL-17F-type mRNA has been detected in colonic
epithelial cells, indicating its function inmucosal barrier fortifica-
tion (39). It is possible that IL-17F serves as a first frontier of the
mucosal surfaces that is prepared to alarm the recruitment of in-
nate defense army in the case of stress or injury.
Although numerous studies reported TNBS-mediated induc-
tion of the IL-17 cytokine (40), the results of our research revealed
downregulation of IL-17F mRNA 48 h after TNBS injury. One of
the possible explanations was suggested by Ruyssers et al. (41),
where IL-17 mRNA transcription as an early response to stress
stimuli is counterregulated by the protective host response
mounted in later phases of the acute response.
Data available from the literature pointed to the strain-depen-
dent effects of lactobacilli in acute inflammatory phase of TNBS-
induced colitis (42). Although the protective role of TNF- has
been demonstrated for this model (43), the observed protective
abilities of lactobacilli were attributed to their anti-inflammatory
actions in the GI tract (9). There are no published data that would
associate the time-varying reaction of colonic tissue to ingested
bacteria with the inflammation induced after TNBS damage in a
defined time point with respect to the length of bacterial treat-
ment. Chemical damage by TNBS in our study was inflicted in the
moment that, according to histological and cytokine-level evalu-
ations, corresponded to the immune reaction of colonic tissue to
BGHI14. Since TNBS inducesmucosal damage that is perpetuated
by superinfection with luminal bacteria (44), it might be expected
that the presence of virulent microbes would substantially exacer-
bate the disease score.However, no adverse effects or amelioration
of acute inflammatory pathology by BGHI14 treatment was ob-
served.
The timing of TNBS administration relative to the barrier
breaching moment as well as the dose instilled are variables influ-
encing the outcome of lactobacillus pretreatment in examined
disease model. Depending on the TNBS dose applied, protection
might not be achieved in an early inflammation phase but with
resolution in late acute or chronic phases of disease (45). A study
was published in which the aggravation of colitis was observed in
the first week of postinduction treatment with tested bacteria, and
at the later time point, a protective effect of probiotic administra-
tion was observed (26). This implies that the inflammatory reac-
tion of the colonic mucosa to ingested lactobacilli might occur in
the first few days of treatment, as observed in our study.
Heat shock proteins (HSP) are crucial for cellular resistance to
environmental stress, and the expression of Hsp70 is increased at
colonic mucosa surfaces due to continuous exposure to luminal
stressors. Accordingly, in the case of bowel inflammation, Hsp70
expression is considered to play an important role in GI tract
barrier maintenance (46). Induction of heat shock proteins by
probiotics, including lactobacilli, in injured GI mucosa has been
reported, and these findings were substantiated by in vitro systems
using intestinal epithelial cells (47). Nevertheless, decreased
Hsp70 expression with a posttranscriptional level of regulation
was observed in inflamed bowel tissue (48). In the present study,
we demonstrated the upregulation of Hsp70 mRNA in colitic rats
treated with BGHI14, which is in agreement with the effects de-
scribed for nonpathogenic bacteria on cytoprotective protein in-
duction (49). Moreover, our results showed no change in Hsp70
transcription after colitis induction. As mentioned above, post-
transcriptional regulation might be involved in the acute phase of
TNBS-caused inflammation. Moreover, elevated Hsp70 mRNA
synthesis was observed in 28-day healthy control and bacterium-
treated groups, which could be attributed to milk’s effects on the
increase of overall microbial count in the rat’s colon, as reported
previously (32).
Tight junction proteins (Tjp) are key stabilizers of the epithe-
lial barrier, lactobacilli are well known to influence that function,
and most studies described posttranscriptional regulation of Tjp
expression and localization in intestinal enterocytes (47). How-
ever, in our study, healthy rats from the 28-day control group
presented higher levels of Tjp1mRNA than 16-day treatment con-
Lukic et al.
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trol rats. Aside from potential prebiotic milk effects (32), this
could also be the result of epithelial “maturation” due to the pro-
gression from the preadult to adult developmental stage of the
animals. Thus, the effects of lactobacilli could be more pro-
nounced in less “mature” mucosa, which has an implication for
age-related probiotic interventions.
In this study, we have shown that the cellular immune response
of healthy ratmucosa is evident after 16 days of lactobacillus treat-
ment. Although the observed reaction to bacteria subsided after
the prolonged treatment, the obtained results imply that ingested
lactobacilli probably came into close contact with the immune
cells of the lamina propria. Although bacterial prophylaxis did not
lead to exacerbation of colitis pathology in the acute phase, bacte-
rial administration should not be considered innocuous to the
healthy host. Having the above facts, if eventual protection of
probiotics in experimental colitis models is to be achieved, strat-
egies should be developed to consider probiotic safety and the
“vulnerability” of themucosal barrier at themoment the chemical
injury is inflicted.
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